Compare SSTK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | RIGL |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.2M | 683.2M |
| IPO Year | 2012 | 2000 |
| Metric | SSTK | RIGL |
|---|---|---|
| Price | $17.34 | $34.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $25.00 | ★ $43.20 |
| AVG Volume (30 Days) | 273.8K | ★ 287.6K |
| Earning Date | 02-24-2026 | 03-03-2026 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | 66.87 | ★ 2698.26 |
| EPS | 1.69 | ★ 6.20 |
| Revenue | ★ $1,020,010,000.00 | $282,076,000.00 |
| Revenue This Year | $11.41 | $66.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.25 | ★ $5.54 |
| Revenue Growth | 13.06 | ★ 79.13 |
| 52 Week Low | $14.35 | $15.50 |
| 52 Week High | $29.96 | $52.24 |
| Indicator | SSTK | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 43.10 |
| Support Level | $17.83 | $33.23 |
| Resistance Level | $19.34 | $34.99 |
| Average True Range (ATR) | 0.92 | 1.46 |
| MACD | -0.19 | 0.15 |
| Stochastic Oscillator | 0.76 | 43.31 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.